Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 0272 • ACR Convergence 2023
Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study
Marion Peyre¹, Arthur Mageau¹, Marie-cecile Henry Feugeas², Serge Doan², Caroline Halimi², Isabelle Klein³, Tiphaine Goulenok², Chrystelle Francois², Marie-Paule Chauveheid², Thomas Papo¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France, ³Clinique Alleray-Labrouste, Paris, France
Background/Purpose: Susac syndrome (SuS) is a rare vasculitis affecting the brain, retina and inner ear in young women. Nonreversible hearing loss is the main long-term…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 0281 • ACR Convergence 2023
Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?
Kristin Schmiedeberg¹, Anna-Lena Walter¹, Lukas Joos¹, Martin Brutsche¹, Johannes von Kempis² and Andrea Rubbert-Roth¹, ¹Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland
Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…
Abstract Number: 1940 • ACR Convergence 2023
A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Tegveer Sandhu¹, Lea Meir², Nicole Ng¹, Lila Klein¹, Jigna Zatakia¹, Maria Padilla¹ and Ioannis Tassiulas¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Icahn School of Medicine, New York, NY
Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…
Abstract Number: 0340 • ACR Convergence 2023
Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study
Chiara Gasteiger¹, Maria Lobo², Robin Stanley¹, Lun Shen Wong¹, Rachel Murdoch¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand
Background/Purpose: Patients are frequently transitioned to biosimilars to reduce the cost burden of biologics. Brand changes can be daunting for patients who have concerns about…
Abstract Number: 1941 • ACR Convergence 2023
Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations
Eduardo Martin-Nares¹, Beatriz E. Sánchez-Hernández², Peter Grayson³, Jose Crispin¹, Daniel Montante-Montes de Oca², Andrea Hinojosa-Azaola¹, Gabriela Hernandez-Molina¹, Elia Apodaca⁴, Emma M. Groarke⁵, Jesús Delgado-de la Mora², Silvia Méndez-Flores⁶, Armando Gamboa-Domínguez², Bhavisha Patel⁷ and Marcela Ferrada⁸, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁴Department of Oncology and Hematology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD, ⁶Department of Dermatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷National Institutes of Health, Beltsville, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited information on VEXAS syndrome in the Latin-American population. We aimed to identify UBA1 mutations causing VEXAS syndrome in Mexican patients presenting…
Abstract Number: 0713 • ACR Convergence 2023
IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis
Edwin Ulises Cortez-Domínguez¹, Gabriela Hernandez-Molina¹, Norma Ofelia Uribe-Uribe², María J Lizardo-Thiebaud² and Eduardo Martin-Nares¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Constrictive pericarditis (CP) is a type of diastolic heart failure characterized by impaired cardiac filling due to the presence of an inelastic pericardium. Histologically,…
Abstract Number: 1942 • ACR Convergence 2023
Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases
Carmen Lasa¹, Joy Selene Osorio², David Martínez-Lopez³, Carmen Alvarez Reguera⁴, Virginia Portilla⁵, Jose Cifrian⁶, Ivan Ferraz Amaro⁷ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Patients with rheumatic immune-mediated inflammatory diseases (rheumatic-IMID) with latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at anincreased risk of developing active tuberculosis…
Abstract Number: 1004 • ACR Convergence 2023
Telerheumatology Shared-Care Model: Leveraging the Expertise of an ACPAC-Trained Extended Role Practitioner (ERP) in Rural-Remote Ontario
Amanda Steiman¹, Taucha Inrig², Katie Lundon³, Jocelyne Murdoch⁴ and Rachel Shupak⁵, ¹Sinai Health System, Toronto, ON, Canada, ²St. Michael's Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Arthritis Society, Toronto, ON, Canada, ⁵St. Michael's Hospital/University of Toronto, Toronto, ON, Canada
Background/Purpose: A shortage of Rheumatologists has led to gaps in inflammatory arthritis (IA) care in Canada. Amplified in rural-remote communities, the number of Rheumatologists practicing…
Abstract Number: 2520 • ACR Convergence 2023
Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis
Carmen Lasa¹, Raul Fernandez-Ramon², Jorge Javier Gaitán², Jose Luis Martin-Varillas³, Rosalía Demetrio², Ivan Ferraz Amaro⁴, Santos Castañeda⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Hospital de la Princesa, Madrid, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Sarcoidosis is a disease with heterogeneous clinical presentation and course. The objective of this study is the identification of clinical phenotypes using cluster analysis.…
Abstract Number: 1005 • ACR Convergence 2023
Telemedicine for Rheumatology Care: A Randomized, Single-Blind, Parallel Group, Noninferiority Trial
Lesley E. Jackson¹, Jinoos Yazdany², Kiara Aaron¹, Sarah Goglin³, Mary Margaretten², David Chae⁴, Jeffrey Curtis¹, Diana Paez⁵, Gary Cutter¹, Kenneth Saag¹ and Maria I. ("Maio") Danila⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of California San Francisco, San Francisco, CA, ³University of California San Francisco, Burlingame, CA, ⁴Tulane University School of Public Health & Tropical Medicine, New Orleans, LA, ⁵University of California San Francisco, Department of Medicine/Rheumatology, San Francisco, CA, ⁶University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: In the wake of the COVID-19 pandemic, telemedicine rapidly became standard of care for people with rheumatic diseases. Observational data on effectiveness and acceptability…
Abstract Number: 1061 • ACR Convergence 2023
Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Chani-mi Lee¹, Margaret Wang², Aarthi Rajkumar¹, Cassandra Calabrese³ and Leonard Calabrese³, ¹University Hospital, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known…
Abstract Number: 1071 • ACR Convergence 2023
No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)
Madeline O'Sullivan¹, Grant Cannon¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel⁴, Jessica A Walsh⁵, Punyasha Roul⁶, Bryant England⁶, Ted R Mikuls⁷, Joshua Baker⁸ and Tawnie Braaten⁴, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴University of Utah, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) are used to treat multiple cancers with increasing frequency and have led to improved survival. However, there is limited data…
Abstract Number: 1079 • ACR Convergence 2023
Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements
Tawnie Braaten¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵ and Grant Cannon⁵, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Immune Checkpoint Inhibitor (ICI)-induced myositis (ICI-myositis) is a rare, but potentially fatal complication of ICI therapy.Electronic health record (EHR) databases are essential to accrue…
Abstract Number: 1149 • ACR Convergence 2023
Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series
Tessalyn Morrison¹, Taylor Lakusta-Wong¹, Chantal Roy-Hewitson¹, Jeanne Gosselin² and Alana Nevares³, ¹University of Vermont, Burlington, VT, ²University of Vermont Medical Center, Waterbury, VT, ³University of Vermont, Essex Junction, VT
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granuloma formation affecting the lung, lymphatics, heart, skin, eye, kidney, and, in neurosarcoidosis, the nervous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].